To amend title 38, United States Code, to direct the Secretary of Veterans Affairs to furnish an opioid antagonist to a veteran without requiring a prescription or copayment.
Summary
HR5999, a bill to direct the VA to furnish opioid antagonists to veterans without a prescription or copayment, has been reported out of committee and awaits floor action. The bill authorizes no specific funding and does not directly affect publicly traded companies, as it mandates a change in VA pharmacy policy rather than creating a procurement or reimbursement program. Market impact is minimal.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR5999 is a VA operational mandate with no direct impact on publicly traded companies.
- 2.The bill authorizes no funding and does not create a new market or procurement program.
- 3.Market impact is minimal; no tickers meet the confidence threshold for inclusion.
Market Implications
No market implications. The bill does not affect any publicly traded company's revenue, costs, or competitive position. The VA's purchase of opioid antagonists is a small, existing expense that will not materially shift pharmaceutical company earnings.
⚡ Government Convergence
Active government convergence in this signal’s sector right now.
Over the last 90 days, 25 separate government actions have converged on VA / Government Health IT. What that means: federal dollars are already moving — agencies are soliciting bids and awarding contracts, not just talking, and legislation and executive action are building the policy and funding tailwind behind it. When independent channels move together like this — 13 bills, 9 federal contracts and 3 procurement notices — it's the clearest early tell that Washington is committing to va / government health it, the kind of build-up that reshapes the sector well before it's obvious in the headlines.
Converging government actions
- ContractTRIWEST HEALTHCARE ALLIANCE CORP: $903M Department of Veterans Affairs Contract · 2026-06-25
- ContractTRIWEST HEALTHCARE ALLIANCE CORP: $874M Department of Veterans Affairs Contract · 2026-06-25
- ContractOPTUM PUBLIC SECTOR SOLUTIONS, INC.: $641M Department of Veterans Affairs Contract · 2026-06-17
- ContractOPTUM PUBLIC SECTOR SOLUTIONS, INC.: $598M Department of Veterans Affairs Contract · 2026-06-17
- ContractOPTUM PUBLIC SECTOR SOLUTIONS, INC.: $773M Department of Veterans Affairs Contract · 2026-06-17
- Procurement noticeX1DB--Department of Veterans Affairs HISTORIC REUSE OPPORTUNITY Robley Rex VAMC located in Louisville, KY · 2026-06-26
- Procurement notice6920--Virtual Reality Training System Complete VR Participant Kit for the Department of Veterans Affairs Vancouver Campus · 2026-06-25
- Procurement noticeVeterans Affairs Medical Center in Washington, DC Medical Transcription Anatomic Pathology · 2026-06-25
Full Analysis
HR5999, introduced by Rep. Conaway (D-NJ), would require the Secretary of Veterans Affairs to provide opioid antagonists (e.g., naloxone) to veterans without requiring a prescription or copayment. The bill was ordered to be reported (amended) by voice vote on May 14, 2026, and now awaits floor action in the House. It has 4 cosponsors and is referred to the House Committee on Veterans' Affairs.
The bill authorizes no specific funding amount — it mandates a change in VA pharmacy policy, not a new procurement or grant program. The VA would absorb the cost of furnishing opioid antagonists without copayment, which is a relatively small operational expense within the VA's existing budget. There is no direct money trail to public companies; the VA purchases naloxone and similar drugs through its own supply chain, and the volume increase from this mandate is unlikely to materially affect pharmaceutical manufacturers' revenue.
No convergence signals were provided in the enrichment data. The bill is a standalone procedural action with no related bills, amendments, or presidential actions to analyze.
Structural winners and losers: None. The bill is a VA operational mandate with no direct impact on publicly traded companies. Pharmaceutical manufacturers of naloxone (e.g., $TEVA, $MYL, $AMPH) could see a minor volume increase, but the VA's purchasing volume is a small fraction of the overall naloxone market, and the mandate does not change pricing or market structure. The bill does not create a new market or funding stream.
Timeline: The bill has been reported out of committee and awaits floor action in the House. If passed, it would go to the Senate. Given the procedural stage and lack of controversy, passage is possible but not guaranteed in the current session.
Key Legislators
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $598M Department of Veterans Affairs Contract
TRIWEST HEALTHCARE ALLIANCE CORP: $903M Department of Veterans Affairs Contract
TRIWEST HEALTHCARE ALLIANCE CORP: $874M Department of Veterans Affairs Contract
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $773M Department of Veterans Affairs Contract
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $641M Department of Veterans Affairs Contract
FIRST NATION GROUP LLC: $17.7M Department of Veterans Affairs Contract
A bill to amend titles 10 and 38, United States Code, and other Federal laws, to improve benefits for veterans and the administration of the Department of Veterans Affairs.
TRIWEST HEALTHCARE ALLIANCE CORP: $29.8M Department of Veterans Affairs Contract
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Advancing Regenerative Agriculture and Strengthening American Farm Resilience
This executive order directs the EPA, USDA, and HHS to prioritize registration of alternative pesticides, expedite cumulative exposure research, and maximize funding for a regenerative agriculture pilot program, while creating public-private partnerships to expand adoption of conservation farming practices. The order specifically instructs the EPA Administrator to speed up registration actions for substances that can replace older active ingredients, and requires HHS to issue a grand prize challenge for cumulative chemical exposure evaluation technologies.
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →